Skip to main content

Table 1 Rheumatoid arthritis characteristics of the 30-day mortality group at ICU admission

From: Prognostic factors for the short-term mortality of patients with rheumatoid arthritis admitted to intensive care units

Characteristic All patients
(n = 67)
30-day mortality
Survivors
(n = 52)
Nonsurvivors
(n = 15)
P-value
Age (years) 68.3 ± 13.5
(70, 33–96)
66.9 ± 14.4
(70, 33–96)
73.1 ± 8.5
(75, 54–85)
0.1484
Sex (female/male) 47/20
(70%/30%)
39/13
(75%/25%)
8/7
(53%/47%)
0.1062
RA duration (years) 13.9 ± 15.0
(10, 0–61)
14.1 ± 15.7
(9, 0–61)
12.9 ± 12.9
(10, 1–48)
0.7120
Steinbrocker
 Stage (I/II/III/IV) 9/19/18/21
(13%/28%/27%/31%)
9/15/14/17
(13%/29%/27%/31%)
2/4/4/5
(13%/27%/27%/33%)
0.9975
 Class (1/2/3/4) 7/16/38/6
(10%/24%/57%/9%)
8/14/29/4
(12%/25%/56%/8%)
1/3/9/2
(7%/20%/60%/13%)
0.8407
Medication
 bDMARDs 6 (9%) 6 (12%) 0 (0%) 0.1680
 csDMARDs 37 (55%) 30 (57.7%) 7 (46.7%) 0.4493
 MTX 19 (28%) 17 (33%) 2 (13%) 0.1428
 MTX dose (mg) 6.4 ± 2.1 (6, 4–12) 6.2 ± 1.7 (6, 4–8) 8.0 ± 5.7 (8, 4–12) 0.7267
 Othersa 24 (36%) 18 (35%) 6 (40%) 0.7016
 Glucocorticoids 53 (79%) 38 (73.1%) 15 (100%) 0.0239
 Glucocorticoid dose (mg)
(conversion of prednisone)
5.3 ± 5.3
(5, 0–25)
4.5 ± 5.0
(4, 0–25)
8.1 ± 5.8
(7, 1–25)
0.0095
30-day mortality 15/67 (22%)    
90-day mortality 18/67 (27%)    
1-year mortality 23/62 (37%)    
  1. Data represent mean ± SD (median, range)
  2. bDMARDs biologic disease-modifying anti-rheumatic drugs, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, MTX methotrexate, RA rheumatoid arthritis
  3. aOthers of csDMARDs contained tacrolimus, salazosulfapyridine, bucillamine, mizoribine, iguratimod, and cyclosporine